NRAS mutant: Gene Variant Detail - Cancer Knowledgebase (CKB)

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT06106308	Phase II	Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	Recruiting	USA	0
NCT04515394	Phase II	Cetuximab + Tepotinib	Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)	Terminated	USA \| ITA \| GBR \| FRA \| ESP \| CZE \| BEL	1
NCT02607813	Phase I	LXH 254 + Spartalizumab LXH 254	Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations	Terminated	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CHE \| CAN	2
NCT04072198	Phase II	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin	Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NIVACOR)	Completed	ITA	0
NCT05886920	Phase I	D3S-002	Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations	Recruiting	USA \| AUS	1
NCT04734990	Phase Ib/II	Azacitidine + Seclidemstat	Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia	Recruiting	USA	0
NCT02610361	Phase I	Lifirafenib	Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors	Completed	NZL \| AUS	0
NCT06328738	Phase I	ELVN-002 + Eribulin + Trastuzumab Capecitabine + ELVN-002 + Trastuzumab ELVN-002 + Paclitaxel + Trastuzumab Capecitabine + ELVN-002 + Oxaliplatin + Trastuzumab ELVN-002 + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab ELVN-002 + Trastuzumab	ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer	Recruiting	USA \| NLD \| ITA \| FRA \| ESP \| BEL	1
NCT01915602	Phase II	Refametinib + Sorafenib	Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)	Completed	USA \| TUR \| NZL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| BEL \| AUT	7
NCT01693068	Phase II	Dacarbazine Pimasertib	Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma	Completed	USA \| SWE \| NZL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CHE \| BEL \| AUS	1
NCT03698994	Phase II	Ulixertinib	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA	1
NCT03597581	Phase I	RGX202 Fluorouracil + Irinotecan + Leucovorin + RGX202 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + RGX202	A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer	Recruiting	USA	0
NCT04425239	Phase II	Fluorouracil + Irinotecan + Leucovorin + Panitumumab	Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE)	Completed	ITA	0
NCT04189055	Phase II	Cetuximab + Irinotecan Cetuximab	Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL)	Recruiting	FRA	0
NCT05312398	Phase II	Cetuximab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin	CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen	Active, not recruiting	ITA	0
NCT02747537	Phase II	Irinotecan + Sorafenib	Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan	Withdrawn		0
NCT02022982	Phase Ib/II	Mirdametinib + Palbociclib	PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors	Completed	USA	0
NCT04776655	Phase III	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin	Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb)	Unknown status	ITA	0
NCT05564403	Phase II	Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin	Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)	Suspended	USA	0
NCT06445062	Phase Ib/II	Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin + RMC-6236 Gemcitabine + Nab-paclitaxel + RMC-6236 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + RMC-6236 Cetuximab + RMC-6236 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RMC-6236	Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors	Recruiting	USA	0
NCT03919292	Phase Ib/II	Divalproex sodium + Neratinib	Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca	Suspended	USA	0
NCT06005974	Phase II	TAK-733	A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation	Active, not recruiting	USA	0
NCT05379595	Phase Ib/II	Amivantamab-vmjw Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin	A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1)	Recruiting	USA \| ITA \| ESP \| DEU \| CAN \| BEL	5
NCT06297629	Phase II	Decitabine and Cedazuridine	A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation	Withdrawn	USA	0
NCT04511845	Phase I	SPYK04	A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	Active, not recruiting	USA	1
NCT03637491	Phase II	Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib	A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors	Terminated	USA \| BEL	1
NCT01306045	Phase II	Erlotinib Lapatinib MK2206 Sunitinib Selumetinib	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies	Completed	USA	0
NCT04109456	Phase I	BI 853520 + Cobimetinib BI 853520	IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma	Active, not recruiting	USA \| AUS	0
NCT05062889	Phase II	Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin Trifluridine-tipiracil hydrochloride Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib	Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (ERASE-CRC)	Recruiting	ITA	0
NCT01907815	Phase II	Trametinib + Uprosertib	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia	Terminated	USA	0
NCT05253651	Phase III	Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin	A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)	Recruiting	USA \| SVK \| POL \| NOR \| NLD \| ITA \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	6
NCT05356897	Phase II	Trastuzumab + Trifluridine-tipiracil hydrochloride + Tucatinib	Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study	Withdrawn	USA	0
NCT02965417	Phase II	SYM004	Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients	Withdrawn		0
NCT05954871	Phase I	Cetuximab + GDC-1971 GDC-1971 + Osimertinib	Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer	Active, not recruiting	USA \| CAN \| AUS	1
NCT03867799	Phase II	Nivolumab + Relatlimab	iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer	Active, not recruiting	GBR	0
NCT05203172	FDA approved	Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib	The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials	Recruiting	USA \| SVK \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| AUS	4
NCT05039177	Phase Ib/II	Cetuximab + Encorafenib + ERAS-007 ERAS-007 + Palbociclib	A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)	Active, not recruiting	USA	0
NCT04409639	Phase II	Cobimetinib	Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO)	Recruiting	USA	0
NCT03317119	Phase I	Trametinib + Trifluridine-tipiracil hydrochloride	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	Completed	USA	0
NCT04808362	Phase Ib/II	OMO-103	Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure)	Terminated	ESP	0
NCT03181100	Phase II	Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel	Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer	Active, not recruiting	USA	0
NCT02974725	Phase I	LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma	Terminated	USA \| SWE \| POL \| ITA \| ISR \| FRA \| ESP \| DEU \| BEL \| AUS	1
NCT05786924	Phase I	BDTX-4933	A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers	Active, not recruiting	USA	0
NCT06026410	Phase I	Cabozantinib + KO-2806 Adagrasib + KO-2806 KO-2806	KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001)	Recruiting	USA	0
NCT02285439	Phase Ib/II	Binimetinib	Study of MEK162 for Children With Low-Grade Gliomas	Active, not recruiting	USA	0
NCT05182931	Phase II	Dabrafenib + Trametinib Trametinib	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (I-FIRST)	Recruiting	AUS	0
NCT04616183	Phase Ib/II	Abemaciclib + Cetuximab + LY3214996 Cetuximab + LY3214996	LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer	Active, not recruiting	USA	0
NCT04985604	Phase Ib/II	Pimasertib + Tovorafenib Tovorafenib	Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors	Active, not recruiting	USA \| FRA \| ESP \| CAN \| BEL \| AUS	1
NCT06509126	Phase III	Fluorouracil + Irinotecan + Leucovorin + Panitumumab	Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE-2)	Recruiting	ITA	0
NCT06750094	Phase III	Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin	A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3)	Recruiting	USA \| TUR \| SWE \| POL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS	9
NCT02630420	Phase I	Cetuximab + Savolitinib	Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer	Withdrawn		0
NCT05223673	Phase III	Trifluridine-tipiracil hydrochloride Futuximab + Modotuximab	Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR)	Terminated	USA \| HUN \| FIN \| DNK \| BEL	1
NCT02224781	Phase III	Ipilimumab + Nivolumab Dabrafenib + Trametinib	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	Active, not recruiting	USA	0
NCT06504459	Phase II	Cladribine + Cytarabine + Venetoclax Azacitidine + Venetoclax	Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML	Recruiting	USA	0
NCT06876142	Phase Ib/II	Mirdametinib + Sirolimus	Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	Not yet recruiting	USA	0
NCT03732703	Phase Ib/II	Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide	Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)	Completed	USA	0
NCT06007924	Phase II	Defactinib + RO5126766	A Study of Avutometinib and Defactinib in People With Thyroid Cancer	Recruiting	USA	0
NCT04835805	Phase I	Belvarafenib + Cobimetinib + Nivolumab Belvarafenib + Cobimetinib Belvarafenib	A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.	Active, not recruiting	USA \| NOR \| DEU \| CAN \| AUS	1
NCT03613532	Phase I	Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine	Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	Recruiting	USA	0
NCT04310176	Phase II	Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil Bevacizumab + Fluorouracil + Valproic acid Bevacizumab + Capecitabine + Valproic acid Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Valproic acid Bevacizumab + Capecitabine + Oxaliplatin + Valproic acid	Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer (REVOLUTION)	Unknown status	ITA	0
NCT06634875	Phase II	Isunakinra	Isunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS)	Recruiting	USA	0
NCT02648490	Phase I	Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07	An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers	Completed	USA	1
NCT05849662	Phase Ib/II	Azacitidine + Cytarabine + Fludarabine + Trametinib Azacitidine + Trametinib	A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia	Recruiting	USA	0
NCT01737502	Phase Ib/II	Auranofin + Sirolimus	Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer	Completed	USA	0
NCT06011772	Phase I	CIMAvax-EGF Bevacizumab + Cetuximab + CIMAvax-EGF + Leucovorin Bevacizumab + CIMAvax-EGF + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Irinotecan + Leucovorin	EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer	Suspended	USA	0
NCT04417621	Phase II	LTT462 + LXH 254 Trametinib Ribociclib	Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma	Active, not recruiting	USA \| NOR \| NLD \| ITA \| ISR \| GBR \| FRA \| DEU \| CHE \| BEL \| AUS \| ARG	0
NCT05985954	Phase I	Cetuximab + Encorafenib + Ulixertinib Cetuximab + Ulixertinib	Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy	Recruiting	USA	0
NCT06152809	Phase I	Aldesleukin + CIML-NK cells + Venetoclax	CIML NK Cells With Venetoclax for AML	Recruiting	USA	0
NCT04913285	Phase I	Binimetinib + Exarafenib Exarafenib	A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors	Recruiting	USA \| FRA \| ESP \| AUS	2
NCT05217446	Phase II	Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab	A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK)	Active, not recruiting	USA \| SWE \| SVK \| POL \| NOR \| NLD \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BEL \| AUS	0
NCT03875820	Phase I	Defactinib + RO5126766	Phase I Trial of Defactinib and VS-6766. (FRAME)	Active, not recruiting	GBR	0
NCT05831995	Phase I	ABM-168	Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.	Terminated	USA	0
NCT05503797	Phase II	Cobicistat + PLX8394 PLX8394	A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations	Recruiting	USA \| SWE \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN	1
NCT05441514	Phase I	Cobimetinib + Enasidenib	Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	Recruiting	USA	0
NCT01781572	Phase Ib/II	Binimetinib + Ribociclib	A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma	Completed	USA \| NLD \| ITA \| DEU \| AUS	0
NCT02296242	Phase Ib/II	Ulixertinib	Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes	Completed	USA	0
NCT05564377	Phase II	Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Recruiting	USA	1
NCT05983367	Phase II	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RGX202	A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer	Active, not recruiting	FRA \| ESP \| BEL	0
NCT06662786	Phase III	Oxaliplatin Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin	A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (OrigAMI-2)	Recruiting	USA \| TUR \| SWE \| POL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL	7
NCT06299839	Phase I	PAS-004	PAS-004 in Patients With Advanced Solid Tumors	Recruiting	USA \| ROU \| BGR	0
NCT04566393	Expanded access	Ulixertinib	Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies	Available	USA	0
NCT03983993	Phase II	Niraparib + Panitumumab	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect)	Active, not recruiting	USA	0
NCT02140840	Phase II	Trametinib	A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib	Withdrawn	USA	0
NCT02857270	Phase I	LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996	A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer	Completed	USA \| FRA \| AUS	1
NCT03913026	Phase II	ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa	UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia	Active, not recruiting	CAN	0
NCT06346067	Phase III	LXH 254 + Trametinib Trametinib Dacarbazine Temozolomide	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| CZE \| CAN \| AUS	0
NCT05057013	Phase Ib/II	HMBD-001	A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours	Recruiting	GBR	0
NCT06287463	Phase Ib/II	DCC-3084	Study of DCC-3084 in Participants with Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway	Recruiting	USA	0
NCT06411821	Phase II	Ulixertinib	Ulixertinib in People With Histiocytic Neoplasms	Recruiting	USA	0
NCT02407509	Phase I	RO5126766 Everolimus + RO5126766	Phase I Trial of VS-6766 Alone and in Combination With Everolimus (RAF/MEK)	Recruiting	GBR	0
NCT03415126	Phase I	ERAS-007	A Study of ASN007 in Patients With Advanced Solid Tumors	Completed	USA	0
NCT04211337	Phase III	Vandetanib Cabozantinib Selpercatinib	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	Active, not recruiting	USA \| POL \| NLD \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS	5
NCT03874026	Phase II	Cetuximab + Fluorouracil + Irinotecan + Leucovorin	Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (CIFRA)	Recruiting	ITA	0
NCT04800822	Phase I	PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892	PF-07284892 in Participants With Advanced Solid Tumors	Terminated	USA	0
NCT03037385	Phase Ib/II	Pralsetinib	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL	5
NCT05585320	Phase Ib/II	IMM-1-104	A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors	Recruiting	USA	0
NCT05012618	Phase I	LUNA18	A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	Recruiting	USA	1
NCT04034173	Phase II	Fluorouracil + Irinotecan + Leucovorin + Panitumumab	Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation	Not yet recruiting	DEU	0
NCT05706779	Phase II	Cetuximab + Encorafenib	Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer (NEORAF)	Recruiting	FRA	0
NCT03091257	Phase I	Dabrafenib + Trametinib Dabrafenib Trametinib	A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	Recruiting	USA	0
NCT06270082	Phase I	IK-595	Study of IK-595 in RAS- or RAF-altered Advanced Tumors	Recruiting	USA	0
NCT04117945	Phase II	Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab	Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer	Active, not recruiting	USA	0
NCT06369259	Phase II	Cetuximab + Defactinib + RO5126766	Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer	Recruiting	USA	0
NCT02934529	Phase III	Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Capecitabine + Fluorouracil + Leucovorin Regorafenib	Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (AIO-KRK-0114)	Active, not recruiting	DEU	0
NCT05069935	Phase I	Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine	FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors	Terminated	USA	0
NCT03190915	Phase II	Trametinib	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	Active, not recruiting	USA	0
NCT04854434	Phase II	Trifluridine-tipiracil hydrochloride Pembrolizumab + Selinexor Selinexor	A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations	Terminated	USA	0
NCT03162627	Phase I	Olaparib + Selumetinib	Selumetinib and Olaparib in Solid Tumors	Active, not recruiting	USA	0
NCT06533059	Phase I	ALTA-2618	A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors	Recruiting	USA \| AUS	2
NCT05580770	Phase Ib/II	BGB3245 + Mirdametinib	Mirdametinib + BGB-3245 in Advanced Solid Tumors	Terminated	USA \| AUS	0
NCT04599140	Phase Ib/II	Nivolumab + SX-682 SX-682	SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial	Recruiting	USA	0
NCT06578559	Phase II	Cetuximab + Encorafenib	Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (BRICKET)	Recruiting	ITA	0
NCT01781429	Phase Ib/II	Ulixertinib	Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies	Completed	USA	0
NCT06695845	Phase II	Zanidatamab	A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors	Recruiting	USA	0
NCT04708054	Phase II	Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax	Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS	Recruiting	USA	0
NCT03043313	Phase II	Trastuzumab + Tucatinib Tucatinib	Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer	Completed	USA \| ITA \| FRA \| ESP \| BEL	0
NCT04145297	Phase I	Hydroxychloroquine + Ulixertinib	Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH)	Completed	USA	0
NCT06096974	Phase I	TEB-17231	Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS	Not yet recruiting	USA	0
NCT04916236	Phase I	LY3214996 + RMC-4630	Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA)	Terminated	NLD	0
NCT04892017	Phase Ib/II	DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib	A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors	Recruiting	USA	0
NCT02723006	Phase I	Nivolumab + Tovorafenib MLN1202 + Nivolumab Ipilimumab + Nivolumab + Vedolizumab	Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma	Terminated	USA	0
NCT05221320	Phase II	Hydroxychloroquine + Ulixertinib	Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies	Terminated	USA	0
NCT01885195	Phase II	Binimetinib	MEK162 for Patients With RAS/RAF/MEK Activated Tumors	Completed	USA	0
NCT02292758	Phase II	Bevacizumab + Cetuximab + Irinotecan Cetuximab + Irinotecan	Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer	Completed	USA	0
NCT02089230	Phase Ib/II	Binimetinib	MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy	Terminated	USA	0
NCT03714958	Phase I	Siremadlin + Trametinib	Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD)	Completed	FRA	0
NCT06162221	Phase Ib/II	Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Pembrolizumab + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Pembrolizumab + RMC-6291	Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC	Recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DEU	0
NCT05554367	Phase II	Binimetinib + Palbociclib	Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT03213691	Phase II	Selumetinib	Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Completed	USA	1
NCT03051035	Phase I	KO-947	First-in-Human Study of KO-947 in Non-Hematological Malignancies	Terminated	USA \| ESP	0
NCT01449058	Phase Ib/II	Alpelisib + Binimetinib	A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Completed	USA \| ITA \| GBR \| FRA \| ESP \| CHE \| AUS	0
NCT03244956	Phase II	Trametinib Dabrafenib + Trametinib	Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE)	Unknown status	FRA	0
NCT06113289	Phase Ib/II	ASTX029 + Decitabine and Cedazuridine	A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia	Withdrawn		0
NCT06287463	Phase Ib/II	DCC-3084	Study of DCC-3084 in Participants with Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway	Recruiting	USA	0
NCT06106308	Phase II	Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	Recruiting	USA	0

Gene	NRAS
Variant	mutant
Impact List	unknown
Protein Effect	unknown
Gene Variant Descriptions	NRAS mutant indicates an unspecified mutation in the NRAS gene.
Associated Drug Resistance
Category Variants Paths	NRAS mutant

NRAS mutant - Gene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting